CNBX Cannabics Pharmaceuticals Inc.

Cannabics Pharmaceuticals, Inc. is an early stage biotechnology company, which engages in the development of personalized anti-cancer and palliative treatments. It focuses on the research and development of cannabinoid-based diagnostics, anti-cancer pharmaceuticals, and palliative therapies. The company was founded by Itamar Borochov, Eyal Ballan, and Eyal Barad on September 15, 2004 and is headquartered in Bethesda, MD.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.16    OTCQB
As of 09/15/2021     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  05/17/2013
Outstanding shares:  148,661,247
Average volume:  82,838
Market cap:   $23,488,477
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   -34.54
PB ratio:   10.63
PS ratio:   0.00
Return on equity:   -139.16%
Net income %:   -147,033.30%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy